

BIOTECH

Psoriasis Treatment



ERAP*i*

Novel inhibitors of Endoplasmic-Reticulum Aminopeptidases (ERAPs) for the treatment of psoriasis and other autoimmune diseases.

Technology matured by



#Psoriasis

#Autoimmune diseases

#MHC-I disorders



Achievements:

- More than 100 analogues synthesized
- IC₅₀ values ranging from 200 nM to 4 nM
- Potent and selective ERAP2 inhibitors (KTGS chemistry)
- Good ADME properties (current ERAP2 lead)
- *In vivo* Proof of Concept in a psoriasis model
- ERAP-humanized animal model created and available

IP status

PCT - Priority date : Dec. 18th, 2020

EP, US, CA, CN, JP, IL



CONTACT SATT Nord

Mathieu NOWARA Business Developer | mathieu.nowara@sattnord.fr